Topics

Dermavant Enters into Exclusive License Agreement with JT for Development and ...

21:39 EST 14 Jan 2020 | BioMedReports - Blog
  • JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan
  • Dermavant to receive an upfront payment of $60 million, additional pre-commercial milestone payments of up to $53 million, and sales royalties
  • Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) currently in Phase 3 development in the U.S. with topline data expected in 2020

TOKYO and BASEL, Switzerland, Jan. 15, 2020 (GLOBE NEWSWIRE)

Read more...

Original Article: Dermavant Enters into Exclusive License Agreement with JT for Development and ...

NEXT ARTICLE

More From BioPortfolio on "Dermavant Enters into Exclusive License Agreement with JT for Development and ..."

Quick Search

Relevant Topics

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...